Immunovant, Inc. (IMVT) — Financial statements
Income statement, balance sheet, and cash flow for Immunovant, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 361↑69.5% | 213↑32.9% | 160↑57.4% | 102↑48.4% | 69 | |
| General & Administrative Expenses | 77↑34.8% | 57↑19.3% | 48↓11.4% | 54↑37.2% | 40 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 77↑34.8% | 57↑19.3% | 48↓11.4% | 54↑37.2% | 40 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 438↑62.2% | 270↑29.7% | 208↑33.5% | 156↑44.3% | 108 | |
| Total Costs & Expenses | 438↑62.2% | 270↑29.7% | 208↑33.5% | 156↑44.3% | 108 | |
| Operating Results | ||||||
| Operating Income | -438↓62.2% | -270↓29.7% | -208↓33.5% | -156↓44.3% | -108 | |
| Depreciation & Amortization | 0.38↑63.2% | 0.23↑19.7% | 0.19↑53.2% | 0.13↑93.8% | 0.07 | |
| EBITDA | -438↓62.2% | -270↓29.7% | -208↓33.5% | -156↓44.3% | -108 | |
| EBIT | -438↓62.2% | -270↓29.7% | -208↓33.5% | -156↓44.3% | -108 | |
| Interest & Other Income | ||||||
| Net Interest Income | 25↓0.9% | 25↑608.7% | -5 | 0.00 | 0.00 | |
| Interest Income | 25↓0.9% | 25↑229.2% | 8 | — | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 12 | — | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 25↑120.3% | 11↑527.7% | -3↓242.5% | -0.78↓338.1% | 0.33 | |
| Income Before Tax | -413↓59.6% | -259↓22.7% | -211↓34.5% | -157↓45.5% | -108 | |
| Income Tax Expense | 0.89↑57.1% | 0.57↑6200.0% | 0.01↑110.7% | -0.08↑76.5% | -0.36 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -414↓59.6% | -259↓22.9% | -211↓34.6% | -157↓45.9% | -107 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -414↓59.6% | -259↓22.9% | -211↓34.6% | -157↓45.9% | -107 | |
| Bottom-Line Net Income | -414↓59.6% | -259↓22.9% | -211↓34.6% | -157↓45.9% | -107 | |
| EPS (Basic) | -2.73↓45.2% | -1.88↓9.9% | -1.71↓19.6% | -1.43↓17.2% | -1.22 | |
| EPS (Diluted) | -2.73↓45.2% | -1.88↓9.9% | -1.71↓19.6% | -1.43↓17.2% | -1.22 | |
| Weighted Average Shares | 152↑9.8% | 138↑12.2% | 123↑12.2% | 110↑25.0% | 88 | |
| Weighted Average Diluted Shares | 152↑9.8% | 138↑12.2% | 123↑12.2% | 110↑25.0% | 88 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.